Business Wire

European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna

Share

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an additional 150 million doses of the COVID-19 Vaccine Moderna, which are scheduled to be delivered in the third and fourth quarter of 2021. This brings its confirmed order commitment to 310 million doses for delivery in 2021.

Under the terms of the agreement, the European Commission has the option to purchase an additional 150 million doses to be delivered in 2022.

“We appreciate the European Commission’s confidence in Moderna and our mRNA platform. Today’s purchase of an additional 150 million doses brings their total order of our COVID-19 vaccine to 310 million for delivery in 2021,” said Stéphane Bancel, Chief Executive Officer of Moderna. “The European Commission is in discussions with us on how to prepare for 2022, including addressing potential variants, and the Commission has an option for an additional 150 million doses for delivery in 2022. Moderna is committed to working relentlessly to bring to market vaccine boosts with the relevant variants to address this global pandemic.”

The European Commission granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, based upon the recommendation of the European Medicines Agency (EMA) for use of the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older. Deliveries of COVID-19 Vaccine Moderna to European countries have to date come from Moderna’s dedicated non-U.S. supply chain.

About the COVID-19 Vaccine Moderna

The COVID-19 Vaccine Moderna (referred to in the U.S. as the Moderna COVID-19 Vaccine) is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the U.S. National Institute of Allergy and Infectious Disease’s (NIAID) Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the U.S. National Institutes of Health (NIH) on February 24, 2020, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of the Moderna COVID-19 Vaccine was dosed on March 16, 2020, 63 days from sequence selection to Phase 1 study dosing. On May 12, 2020, the U.S Food and Drug Administration granted the Moderna COVID-19 Vaccine Fast Track designation. On May 29, 2020, the first participants in each age cohort: adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300) were dosed in the Phase 2 study of the vaccine. On July 8, 2020, the Phase 2 study completed enrolment.

Results from the second interim analysis of the NIH-led Phase 1 study of the Moderna COVID-19 Vaccine in the 56-70 and 71+ age groups were published on September 29 in The New England Journal of Medicine. On July 28, results from a non-human primate preclinical viral challenge study evaluating the vaccine were published in The New England Journal of Medicine. On July 14, an interim analysis of the original cohorts in the NIH-led Phase 1 study of the vaccine was published in The New England Journal of Medicine. On November 30, Moderna announced the primary efficacy analysis of the Phase 3 study of the vaccine conducted on 196 cases. On November 30, the Company also announced that it filed for Emergency Use Authorization with the U.S. FDA and a Conditional Marketing Authorization (CMA) application with the European Medicines Agency. On December 3, a letter to the editor was published in TheNew England Journal of Medicine reporting that participants in the Phase 1 study of the Moderna COVID-19 Vaccine retained high levels of neutralizing antibodies through 119 days following first vaccination (90 days following second vaccination). On December 18, 2020, the U.S. FDA authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age or older. Moderna has also received authorization for its COVID-19 vaccine from health agencies in Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore and Qatar. Additional authorizations are currently under review in other countries and by the World Health Organization.

Authorized Use

The COVID-19 Vaccine Moderna has been granted a Conditional Marketing Authorization by the European Commission, based upon the recommendation of the European Medicines Agency, which authorizes the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s development of a vaccine against the novel coronavirus, and plans for the supply and distribution of the COVID-19 Vaccine Moderna to Member States of the European Union, as well as the timing for that supply. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Moderna Contacts:
Media:
Colleen Hussey
Director, Corporate Communications
617-335-1374
Colleen.Hussey@modernatx.com

Harriet Barham
Director, FTI Consulting
+32 474-819-629
Harriet.Barham@fticonsulting.com
modernamedia@fticonsulting.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NevadaNano Adds Three European Distributors for Its Innovative Molecular Property Spectrometer™ Flammable and Refrigerant Gas Sensors18.5.2021 16:49:00 CEST | Press release

NevadaNano, the world’s leading innovator in gas detection sensor technology, today announced it signed three prominent distributors as it continues its expansion throughout Europe. The companies will provide local support and sales to NevadaNano’s growing customer base for its ground-breaking Molecular Property Spectrometer™ (MPS™) flammable gas sensors. “The addition of these three market-leading companies underscores the demand for an innovative sensor like the MPS, one that redefines the standard after nearly 40 years,” said Gary Collins, General Manager, EMEA for NevadaNano. “We are confident that our novel technology and their deep experience of these companies will help their customers develop leading-edge products with highly accurate and reliable gas detection technology.” Maritex Company, based in Gdynia, Poland, is one of the largest, fast-developing wholesalers of electronic equipment on the Polish market. The company supports customers in Poland, Romania, and Sweden. Gas S

Norsk Titanium Lists On Euronext Growth After Successful USD $38 Million Capital Raise18.5.2021 16:15:00 CEST | Press release

Norsk Titanium AS (Norsk Titanium), a global leader in the additive manufacturing of aerospace-grade titanium components, has satisfied the conditions for listing on the Euronext Growth Oslo. Norsk Titanium’s first day of trading on the exchange was May 18th under the ticker code NTI. The listing follows a successful share issue through a private placement that raised approximately USD $38 million. Leading shareholders, represented on the Board of Directors, participated in the private placement with USD $15 million, and the Norwegian family-owned investment company Ferd AS participated with USD $10 million. Norsk Titanium intends to use the proceeds from the private placement to fund planned growth initiatives. “Today marks an important milestone for Norsk Titanium,” said Michael Canario, Norsk Titanium’s CEO. “The funding enabled through the Euronext Growth listing will support our ongoing development activities with our commercial customers as well as assist the transition of our te

How Dahua Technology Helps Prevent Forest Fires18.5.2021 15:45:00 CEST | Press release

It takes decades for trees to grow, yet only minutes for fires to destroy them. Forest fires are the type of natural disaster that strike with sudden destructiveness and are often difficult to control. That’s why working to prevent forest fires and the damage they cause to natural resources — as well as people’s property and sometimes human life — is a priority for Dahua Technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005588/en/ Dahua Solution Safeguarding The Yarlung Zangbo Grand Canyon (Photo: Business Wire) Over the years, Dahua Technology has developed and deployed capabilities for comprehensive technical support in forest and grassland fire monitoring as well as early warning, forecasting, rescue and post-disaster assessment with digital intelligence technology. Dahua’s technology fully integrates video perception systems with integrated sky and ground monitoring methods to form a strong "fire net" aime

Board International Strengthens Board of Directors to Drive Continued International Expansion and Accelerated Growth18.5.2021 15:35:00 CEST | Press release

Board International, the #1 SaaS Decision-Making-Platform vendor, announces today that Marco Limena will join the Board of Directors of the company as Non-Executive Director and Senior Advisor. Mr. Limena has held senior executive positions in leading technology corporations, including Microsoft, where he was based in Redmond, and at HP, based in Palo Alto. He has extensive experience working with leading Private Equity firms in multiple CEO assignments for B2B growth-oriented software businesses, and as Board Director in both private and publicly listed companies, and industry associations. Based in London, Marco Limena is CEO of TOMIA, a global provider of software solutions designed to accelerate the transformation and monetization of carriers’ connectivity business, with Data, Financial Clearing and BI solutions. Previously at Microsoft, Mr. Limena was Vice President of Hosting & Cloud, responsible for B2B commercial operations of the company’s cloud and infrastructure services bus

Pricefx Named a Finalist for 2021 SAP ® Pinnacle Award in the Partner of Year – Endorsed Apps Category18.5.2021 15:30:00 CEST | Press release

Pricefx, the global leader in cloud-native pricing software, today announced that it has been recognized by SAP as a finalist for a 2021 SAP® Pinnacle Award in the Partner of the Year – Endorsed Apps category. This award recognizes an SAP partner that has created a world-class SAP endorsed app that complements SAP technologies and has contributed a significant amount of value to SAP and its end customers. Last year, Pricefx was a finalist for SAP App Center Partner of the Year. The annual SAP Pinnacle Awards acknowledge the contributions of leading SAP partners that have excelled in developing and growing their partnership with SAP and helping customers meet their goals. Finalists and winners in 28 categories were chosen based on recommendations from SAP, customer feedback and performance indicators. SAP Endorsed Apps are premium certified by SAP with added security, in-depth testing and measurements against benchmarks results. A leader in price optimization, Pricefx’s SAP endorsed app

Andersen Global Broadens Coverage in Liechtenstein and Switzerland18.5.2021 15:30:00 CEST | Press release

Andersen Global adds legal capabilities in Liechtenstein and Switzerland through a Collaboration Agreement with NSF, strengthening the organization’s platform as it continues its expansion in the region. With offices in Vaduz and Zurich, NSF operates with five Partners and 40 professionals, serving individuals and international corporations. The full-service location in Liechtenstein provides a range of services in legal, trust and asset management with capabilities in banking and capital markets, tax, corporate, M&A, arbitration and dispute resolution, contracts, and administrative and constitutional law. Additionally, the office in Switzerland operates as an independent Swiss law firm and offers services in various areas of business law, such as criminal tax law, corporate/M&A, succession planning, inheritance law, litigation, restructuring, debt enforcement and insolvency, employment, financial markets as well as commercial contracts. “For more than 30 years, our extensive experienc

Heise Medien relies on the Xpublisher editorial system18.5.2021 15:04:00 CEST | Press release

Heise Medien GmbH & Co. KG, one of Germany’s leading tech industry publishers, succeeded in establishing transparent and well-organized content and media asset management together with a highly streamlined production process for its magazines by implementing Xpublisher. Xpublisher supports content utilization along the entire value chain, from planning, editorial creation, editing, and layout to the final publication, based on a “content first” approach. This enables Heise Medien to publish across multiple channels in a way that is highly efficient, cost effective, and error free. "We are pleased that Heise Medien trusts in our expertise and successfully automates their magazine production with our editorial system", says Matthias Kraus, CEO of Xpublisher. The numbers are a testament to the project’s success: Instead of the typical production phase of ten days, the first issue of c't was ready for printing in just nine days. In digital production, the company succeeded in both enhancin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom